Chengdu Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CHENGDU, and what generic and branded alternatives to CHENGDU drugs are available?
CHENGDU has three approved drugs.
Drugs and US Patents for Chengdu
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chengdu | TACROLIMUS | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 215012-002 | Jan 25, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Chengdu Shuode | NALMEFENE HYDROCHLORIDE | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 216007-002 | Nov 15, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Chengdu | TACROLIMUS | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 215012-003 | Jan 25, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Chengdu | TACROLIMUS | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 215012-001 | Jan 25, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Chengdu Shuode | NALMEFENE HYDROCHLORIDE | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 216007-001 | Nov 15, 2023 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Chengdu Shuode | NICARDIPINE HYDROCHLORIDE | nicardipine hydrochloride | INJECTABLE;INJECTION | 217548-001 | Sep 6, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.